Edwards Lifesciences Corporation NYSE EW Investment analysts at Leerink Swann decreased their FY2017 EPS estimates for shares of Edwards Lifesciences Corporation in a report issued on Tuesday Leerink Swann analyst D Antalffy now anticipates that the medical research company will earn 3 74 per share for the year down from their previous forecast of 3 75 Leerink Swann also issued estimates for Edwards Lifesciences Corporation s FY2018 earnings at 3 94 EPS Edwards Lifesciences Corporation NYSE EW last issued its quarterly earnings data on Wednesday July 26th The medical research company reported 1 08 earnings per share EPS for the quarter beating the Thomson Reuters consensus estimate of 0 88 by 0 20 Edwards Lifesciences Corporation had a net margin of 22 16 and a return on equity of 27 17 The company had revenue of 842 00 million during the quarter compared to the consensus estimate of 839 16 million During the same quarter last year the company earned 0 76 earnings per share Edwards Lifesciences Corporation s revenue for the quarter was up 10 9 on a year over year basis COPYRIGHT VIOLATION NOTICE This report was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal If you are viewing this report on another publication it was illegally stolen and republished in violation of international copyright trademark law The correct version of this report can be viewed at https www dispatchtribunal com 2017 10 24 edwards lifesciences corporation to post fy2017 earnings of 3 74 per share leerink swann forecasts ew html EW has been the topic of a number of other research reports Canaccord Genuity reiterated a buy rating and issued a 150 00 price objective on shares of Edwards Lifesciences Corporation in a research note on Wednesday June 28th Cowen and Company reiterated a buy rating and issued a 135 00 price objective on shares of Edwards Lifesciences Corporation in a research note on Thursday BidaskClub upgraded shares of Edwards Lifesciences Corporation from a buy rating to a strong buy rating in a research note on Thursday June 22nd Zacks Investment Research lowered shares of Edwards Lifesciences Corporation from a strong buy rating to a hold rating in a research note on Monday July 17th Finally Bank of America Corporation increased their price objective on shares of Edwards Lifesciences Corporation from 140 00 to 150 00 and gave the stock a buy rating in a research note on Thursday July 27th Seven research analysts have rated the stock with a hold rating fifteen have issued a buy rating and one has issued a strong buy rating to the company s stock Edwards Lifesciences Corporation has an average rating of Buy and an average target price of 120 75 Shares of Edwards Lifesciences Corporation NYSE EW opened at 108 25 on Friday The firm has a 50 day moving average of 111 37 and a 200 day moving average of 111 44 The firm has a market cap of 22 86 billion a P E ratio of 32 83 and a beta of 0 62 Edwards Lifesciences Corporation has a 12 month low of 81 12 and a 12 month high of 121 45 In other Edwards Lifesciences Corporation news VP Donald E Bobo Jr sold 5 300 shares of the stock in a transaction on Friday July 28th The shares were sold at an average price of 114 68 for a total transaction of 607 804 00 The transaction was disclosed in a filing with the SEC which can be accessed through this hyperlink Also VP Catherine M Szyman sold 4 681 shares of the stock in a transaction on Monday July 31st The shares were sold at an average price of 115 78 for a total transaction of 541 966 18 The disclosure for this sale can be found here Over the last ninety days insiders have sold 182 201 shares of company stock worth 20 768 154 Insiders own 2 13 of the company s stock A number of institutional investors and hedge funds have recently bought and sold shares of EW Teachers Advisors LLC lifted its holdings in Edwards Lifesciences Corporation by 26 6 during the first quarter Teachers Advisors LLC now owns 835 393 shares of the medical research company s stock valued at 78 585 000 after purchasing an additional 175 457 shares in the last quarter TIAA CREF Investment Management LLC lifted its stake in shares of Edwards Lifesciences Corporation by 32 3 in the first quarter TIAA CREF Investment Management LLC now owns 1 717 227 shares of the medical research company s stock worth 161 540 000 after buying an additional 419 266 shares in the last quarter Bridgewater Associates LP purchased a new position in shares of Edwards Lifesciences Corporation in the first quarter worth about 4 272 000 California Public Employees Retirement System lifted its stake in shares of Edwards Lifesciences Corporation by 1 8 in the first quarter California Public Employees Retirement System now owns 459 900 shares of the medical research company s stock worth 43 263 000 after buying an additional 8 200 shares in the last quarter Finally FDO Partners LLC lifted its stake in shares of Edwards Lifesciences Corporation by 131 8 in the first quarter FDO Partners LLC now owns 43 261 shares of the medical research company s stock worth 4 070 000 after buying an additional 24 594 shares in the last quarter 82 12 of the stock is currently owned by institutional investors and hedge funds Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient s diseased or defective heart valve The Company is engaged in patient focused innovations for structural heart disease and critical care monitoring Its segments include United States Europe Japan and Rest of World Receive News Ratings for Edwards Lifesciences Corporation Daily Enter your email address below to receive a concise daily summary of the latest news and analysts ratings for Edwards Lifesciences Corporation and related companies with MarketBeat com s FREE daily email newsletter